Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Outlook Therapeutics Inc OTLK

Healthcare Biotechnology
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD)... see more

Recent & Breaking News (NDAQ:OTLK)

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire December 23, 2023

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

TheNewsWire December 23, 2023

Berger Montague PC Files a Securities Fraud Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK) With Expanded Class Period

Newsfile December 23, 2023

Outlook Shareholder Alert

Newsfile December 23, 2023

OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Actively Participate in the Class Action Lawsuit!

Accesswire December 23, 2023

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 22, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook Lawsuit - OTLK

Accesswire December 22, 2023

Outlook Therapeutics, Inc. (OTLK) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by January 2, 2024

Newsfile December 22, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc. (OTLK) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire December 22, 2023

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU

GlobeNewswire December 22, 2023

OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Actively Participate in the Class Action Lawsuit!

Accesswire December 22, 2023

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $500,000 to Contact the Firm

Accesswire December 21, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 - OTLK

Accesswire December 21, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire December 21, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 21, 2023

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook Lawsuit - OTLK

Accesswire December 21, 2023

OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options

PR Newswire December 21, 2023

INVESTOR ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 - OTLK

Accesswire December 21, 2023

OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Actively Participate in the Class Action Lawsuit!

Accesswire December 21, 2023

TOP RANKED ROSEN LAW FIRM Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

TheNewsWire December 21, 2023